IPW
REGN icon

Impact Partnership Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Impact Partnership Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$962 – 562
2024
Q1 		$962 Sell
1
-356
-100% -$339K ﹤0.01% 626
2023
Q4 		$314K Buy
357
+356
+35,600% +$293K 0.11% 115
2023
Q3 		$823 Buy
+1
New +$786 ﹤0.01% 905

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Impact Partnership Wealth's REGN Position: Q2 2024 in Review

Impact Partnership Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 1 share — an estimated $962 sold.

Impact Partnership Wealth first reported a position in REGN in Q3 2023 and held it in 3 quarters. The position peaked at $314K in Q4 2023. 1,331 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Impact Partnership Wealth reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Impact Partnership Wealth sold 1 Regeneron Pharmaceuticals share in Q2 2024, an estimated $962.
  • Impact Partnership Wealth first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Impact Partnership Wealth's Regeneron Pharmaceuticals position peaked at $314K in Q4 2023.
  • 1,331 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Impact Partnership Wealth's 13F filing for Q2 2024, filed 2 Aug 2024.